Welcome to our dedicated page for China Pharma SEC filings (Ticker: CPHI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking when China Pharma pivots manufacturing or discloses new drug trial data often means poring over dense regulatory prose. Investors searching for "China Pharma Holdings insider trading Form 4 transactions" or wondering "where is the China Pharma Holdings quarterly earnings report 10-Q filing?" know the challenge of wading through EDGAR’s raw PDFs. The documents run hundreds of pages, tables shift formatting, and key risks hide in footnotes.
Stock Titan delivers AI-powered summaries and instant alerts, turning "China Pharma Holdings Form 4 insider transactions real-time" into easy-to-read dashboards. Our natural-language models provide "China Pharma Holdings SEC filings explained simply" with side-by-side financial ratios, segment sales, and pipeline updates. Drill into drug pricing trends through "China Pharma Holdings earnings report filing analysis" or tap the conversational guide: "understanding China Pharma Holdings SEC documents with AI." All filings stream in seconds after they hit EDGAR, no manual refresh required.
Because pharma disclosures are detail-heavy, our platform shows exactly where R&D spending, clinical milestones, or API supply risks appear in the "China Pharma Holdings executive stock transactions Form 4," the "China Pharma Holdings annual report 10-K simplified," and every "China Pharma Holdings proxy statement executive compensation." Need breaking news? The "China Pharma Holdings 8-K material events explained" module highlights recalls, trials, or CFO changes in plain English. Save hours, spot patterns, and act with confidence.
China Pharma Holdings (CPHI) called its Annual Meeting for December 30, 2025 to vote on three items: re‑elect three independent directors, authorize a reverse stock split of up to 1:20 at the Board’s discretion, and approve Amendment No. 3 to the Amended and Restated 2010 Long‑Term Incentive Plan to increase the share reserve by 500,000 shares (from 69,600 to 569,600).
The reverse split proposal is positioned as a tool to address potential NYSE American “low selling price” concerns; the Board notes prior reverse splits of 1‑for‑5 and 1‑for‑10 in 2024 and 2025. Fractional shares would be rounded up to a full share. Shares outstanding were 5,022,002 as of November 3, 2025, the record date. The proxy outlines standard voting mechanics, quorum (one‑third of outstanding), and recommends voting “FOR” all proposals. The filing also details 2024 audit fees of $125,000 and executive/director compensation, including CEO 2024 salary of $300,000 and outstanding restricted stock of 48,200 under the plan.
China Pharma Holdings (CPHI) reported Q3 2025 results showing continued losses amid tight liquidity. Revenue was $756,217, with a gross loss of $59,654 and net loss of $651,482 (loss per share $0.17). For the nine months, revenue was $2,918,271 and net loss was $1,965,421.
The company flagged substantial doubt about its ability to continue as a going concern. Cash and equivalents were $267,625 as of September 30, 2025, and current liabilities exceeded current assets by $4.3 million. Borrowings from the Chair/CEO totaled $1,413,340, supporting working capital.
Results improved year over year on lower depreciation and reduced inventory obsolescence, narrowing gross loss and operating loss. The company wrote off $13.7 million of long‑aged receivables in August 2025, sharply reducing the allowance. It also issued 1,760,000 shares for a patent asset valued at $2.446 million. A 1‑for‑10 reverse split took effect April 15, 2025; shares outstanding were 5,022,002 as of November 10, 2025.
FAQ
What is the current stock price of China Pharma (CPHI)?
What is the market cap of China Pharma (CPHI)?
